Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm

Psychopharmacology

Volumn 180, Issue 1, 2005, Pages 41-48

  Rukstalis, Margaret ^a   Jepson, Christopher ^a   Strasser, Andrew ^a   Lynch, Kevin G ^a   Perkins, Kenneth ^b   Patterson, Freda ^a   Lerman, Caryn ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Human; Naltrexone; Nicotine; Opiates; Smoking

Indexed keywords

AMFEBUTAMONE; NALTREXONE; NICOTINE; OPIATE ANTAGONIST; PLACEBO;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; FEMALE; FOOD DEPRIVATION; HEADACHE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; REINFORCEMENT; SMOKING CESSATION; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; BUPROPION; CHOICE BEHAVIOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NICOTINE; REINFORCEMENT (PSYCHOLOGY); SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 21244442261     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-2136-8     Document Type: Article

References (68)

1. Almeida LE, Pereira EF, Alkondon M, Fawcett WP, Randall WR, Albuquerque EX (2000) The opioid antagonist naltrexone inhibits activity and alters expression of alpha7 and alpha4beta2 nicotinic receptors in hippocampal neurons: implications for smoking cessation programs. Neuropharmacology 39:2740-2755
2. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E et al (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401
3. Balfour DJ (2002) The neurobiology of tobacco dependence: a commentary. Respiration 69:7-11
4. Boyadjieva NI, Sarkar DK (1997) The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci 61:PL59-PL66
5. Brauer LH, Behm FM, Westman EC, Patel P, Rose JE (1999) Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology (Berl) 143:339-346
6. Brauer LH, Behm FM, Lane JD, Westman EC, Perkins C, Rose JE (2001) Individual differences in smoking reward from denicotinized cigarettes. Nicotine Tob Res 3:101-109
7. Chait LD, Burke KA (1994) Preference for high- versus low-potency marijuana. Pharmacol Biochem Behav 49:643-647
8. Collins BN, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V, Pinto A, Hawk L, Niaura R, Epstein LH, Lerman C (2004) Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res 6:27-37
9. Conte-Devolx B, Oliver C, Giraud P, Gillioz P, Castanas E, Lissitzky JC, Boudouresque F, Millet Y (1981) Effect of nicotine on in vivo secretion of melanocorticotropic hormones in the rat. Life Sci 28:1067-1073
10. Cousins MS, Stamat HM, de Wit H (2001) Acute doses of D-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berlin) 157:243-253
11. Covey LS, Glassman AH, Stetner F (1999) Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis 18:31-40
12. Davenport KE, Houdi AA, Van Loon GR (1990) Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci Lett 113:40-46
13. de Wit H (1996) Priming effects with drugs and other reinforcers. Exp Clin Psychopharmacol 4:5-10
14. de Wit H, McCracken SG (1990) Ethanol self-administration in males with and without an alcoholic first-degree relative. Alcohol Clin Exp Res 14:63-70
15. Epstein AM, King AC (2004) Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav 77:29-37
16. 2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacology 22:1257-1267
17. Ferris RM, Maxwell RA, Cooper BR, Soroko FE (1982) Neuro-chemical and neuropharmacological investigations into the mechanisms of action of bupropion. HCl - a new atypical antidepressant agent. Adv Biochem Psychopharmacol 31:277-286
18. Ferris RM, Cooper BR, Maxwell RA (1983) Studies of bupropion's mechanism of antidepressant activity. J Clin Psychiatry 44:74-78
19. Ferry L, Johnston JA (2003) Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience. Int J Clin Pract 57:224-230
20. Fiore MC, Smith SS, Jorenby DE, Baker TB (1994) The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 271:1940-1947
21. George TP, O'Malley SS (2004) Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 25:42-48
22. Gorelick DA, Rose J, Jarvik ME (1989) Effect of naloxone on cigarette smoking. J Subst Abuse 1:153-159
23. Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, Glover ED, Sachs DP, Hurt RD (1999) Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 174:173-178
24. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict 86:1119-1127
25. Holm KJ, Spencer CM (2000) Bupropion: a review of its use in the management of smoking cessation. Drugs 59:1007-1024
26. Houdi AA, Pierzchala K, Marson L, Palkovits M, Van Loon GR (1991) Nicotine-induced alteration in Tyr-Gly-Gly and Metenkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 12:161-166
27. Houtsmiller EJ, Clemmey PA, Sigler LA, Stitzer ML (1997) Effects of naltrexone on smoking and abstinence. In: Harris LS (ed) Problems of drug dependence 1996: Proceedings of the 58th Annual Scientific Conference. USDHHS, Washington, DC
28. Hughes JR, Shiftman S, Callas P, Zhang J (2003) A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 12:21-27
29. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1202
30. Hurt RD, Wolter TD, Rigotti N, Hays JT, Niaura R, Durcan MJ, Gonzales D, Sachs DP, Johnston JA, Offord KP (2002) Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav 27:493-507
31. Hutchison KE, Monti PM, Rohsenow DJ, Swift RM, Colby SM, Gnys M, Niaura RS, Sirota AD (1999) Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology (Berlin) 142:139-143
32. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685-691
33. Karras A, Kane JM (1980) Naloxone reduces cigarette smoking. Life Sci 27:1541-1545
34. King AC, Meyer PJ (2000) Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav 66:563-572
35. Kogan MJ, Verebey K, Mule SJ (1977) Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. Res Commun Chem Pathol Pharmacol 18:29-34
36. Krishnan-Sarin S, Rosen MI, O'Malley SS (1999) Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch Gen Psychiatry 56:663-668
37. Lee MC, Wagner HN Jr, Tanada S, Frost JJ, Bice AN, Dannals RF (1988) Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 29:1207-1211
38. Litten RZ, Allen JP (1999) Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings. J Subst Abuse Treat 16:105-112
39. Malin DH, Lake JR, Carter VA, Cunningham JS, Wilson OB (1993) Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berlin) 112:339-342
40. Malin DH, Lake JR, Payne MC, Short PE, Carter VA, Cunningham JS, Wilson OB (1996) Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible. Pharmacol Biochem Behav 53:81-85
41. Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC (1984) Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 45:15-19
42. Nemeth-Coslett R, Griffiths RR (1986) Naloxone does not affect cigarette smoking. Psychopharmacology (Berlin) 89:261-264
43. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1990) In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 6:106-112
44. Oliveto AH, Hughes JR, Higgins ST, Bickel WK, Pepper SL, Shea PJ, Fenwick JW (1992) Forced-choice versus free-choice procedures: caffeine self-administration in humans. Psychopharmacology (Berlin) 109:85-91
45. Palmer R, Berens A (1983) Double blind study of the effect of Naloxone on the pleasure of smoking. Fed Proc 42:654
46. Perkins KA, Grobe JE, Weiss D, Fonte C, Caggiula A (1996) Nicotine preference in smokers as a function of smoking abstinence. Pharmacol Biochem Behav 55:257-263
47. Perkins KA, Gerlach D, Broge M, Fonte C, Wilson A (2001) Reinforcing effects of nicotine as a function of smoking status. Exp Clin Psychopharmacol 9:243-250
48. Perkins KA, Broge M, Gerlach D, Sanders M, Grobe JE, Cherry C, Wilson AS (2002) Acute nicotine reinforcement, but not chronic tolerance, predicts withdrawal and relapse after quitting smoking. Health Psychol 21:332-339
49. Peters MJ, Morgan LC (2002) The pharmacotherapy of smoking cessation. Med J Aust 176:486-490
50. Pickworth WB, Fant RV, Nelson RA, Rohrer MS, Henningfield JE (1999) Pharmacodynamic effects of new de-nicotinized cigarettes. Nicotine Tob Res 1:357-364
51. Pierzchala K, Houdi AA, Van Loon GR (1987) Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin. Peptides 8:1035-1043
52. Robinson ML, Houtsmuller EJ, Moolchan ET, Pickworth WB (2000) Placebo cigarettes in smoking research. Exp Clin Psychopharmacol 8:326-332
53. Rose JE, Behm FM, Westman EC, Johnson M (2000) Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol Biochem Behav 67:71-81
54. Rukstalis MR, Stromberg MF, O'Brien CP, Volpicelli JR (2000) 6-beta-naltrexol reduces alcohol consumption in rats. Alcohol Clin Exp Res 24:1593-1596
55. Rusted JM, Graupner L, Greenwood K (1996) Methodological considerations in nicotine research: the use of "denicotinised" cigarettes as the control condition in smoking studies. Psychopharmacology (Berlin) 125:176-178
56. Shahan TA, Bickel WK, Madden GJ, Badger GJ (1999) Comparing the reinforcing efficacy of nicotine containing and de-nicotinized cigarettes: a behavioral economic analysis. Psychopharmacology (Berlin) 147:210-216
57. Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327
58. Sutherland G, Stapleton JA, Russell MA, Feyerabend C (1995) Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology (Berlin) 120:418-425
59. Tiffany ST, Drobes DJ (1991) The development and initial validation of a questionnaire on smoking urges. Br J Addict 86:1467-1476
60. Trulson ME (1985) Activity of dopamine-containing substantia nigra neurons in freely moving cats. Neurosci Biobehav Rev 9:283-297
61. 3H]spiroperidol binding in cat brain. Eur J Pharmacol 117:267-270
62. Verebey K, Volavka J, Mule SJ, Resnick RB (1976) Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 20:315-328
63. Wall ME, Brine DR, Perez-Reyes M (1981) The metabolism of naltrexone in man. NIDA Res Monogr 28:105-131
64. West R (2003) Bupropion SR for smoking cessation. Expert Opin Pharmacother 4:533-540
65. Westman E, Levin E, Rose J (1992) Smoking while wearing the nicotine patch: is smoking satisfying or harmful? Clinical Research 40:871A
66. Wewers ME, Dhatt RK, Snively TA, Tejwani GA (1999) The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkephalin levels in rats. Brain Res 822:107-113
67. Zacny JP, Stitzer ML (1985) Effects of smoke deprivation interval on puff topography. Clin Pharmacol Ther 38:109-115
68. Zacny JP, Stitzer ML, Brown FJ, Yingling JE, Griffiths RR (1987) Human cigarette smoking: effects of puff and inhalation parameters on smoke exposure. J Pharmacol Exp Ther 240:554-564